DIA MASC 2025

Medical Affairs 2.0: GenAI as the Catalyst for Change in Writing, MedComms, and Field Strategy

Digital and AI were hot topics underpinning many of the conversations at the DIA’s Medical Affairs and Scientific Communications (DIA MASC) forum I attended in March 2025, along with a focus on how we can utilize these tools to achieve impactful, engaging, and scientifically accurate communications that resonate with healthcare providers (HCPs) and patients. Along…...
Read More

Top Stories

Biopharma 2025 Trends

Biopharma Trends 2025: 3 Things to Know Right Now

The global business climate is ever-evolving, and 2025 looks...
AI in Medical Affairs & Medical Communications

Science, AI, and Human Ingenuity Converge to

Today, we're witnessing an unprecedented convergence of...

The Paradigm Shift from Traditional Scientific

In the rapidly evolving biopharma landscape, the approach to...
Medical Review

Uncovering the Benefits of Medical Review: A Comprehensive Overview

Medical review promises scientific data accuracy and has paramount importance at all the stages of...
Periodic Safety Update Report (PSUR) - Medical Device

Periodic Safety Update Report (PSUR): A Breakdown of MDCG 2022-21

A well-structured, clear, and concise PSUR enables a seamless notified body review. Read our key...
HEOR Pharma Payers

Didactic to Dynamic: Innovative Approaches to Deeper Payer Engagements

HEOR is a fast-evolving field. Feedback from payers can influence research plans and help create...
Medical Device Regulation

Clinical Evidence: How Much Is Enough?

Ensuring the safety and functionality of your medical device is vital. But how much clinical...

From Transactional to Transformational: Bringing Patient Centricity to the Next Level

The pharma industry’s focus is shifting from the transactional approach to a transformational approach by...
Stakeholder perspectives on digital scientific content

Digital Scientific Content: Stakeholder Perspectives

What do the different relevant stakeholder groups truly expect from pharma-generated scientific content?...

Learn more ABOUT our company.